Beacon
Biotechnology is seeking investors, affiliations and collaborators to
accelerate discovery, leverage complementary technologies and advance
joint and independent programs.
You are invited to download our Executive Summary below, as well as the
scientific papers listed in the
Technology
section:
For more information, please contact Fred Mitchell, CEO, directly at
720.859.6116 or
Forward Looking
Statements
Statements on this website, other than statements of historical fact,
constitute forward looking statements regarding, among other things,
the future business operations of Beacon Biotechnology, LLC or its
subsidiaries (collectively, "the Company").
The Company's actual results may vary materially from those
contemplated in the forward looking statements due to risks and
uncertainties regarding the Company's ability to obtain capital
resources needed to conduct the time consuming research, preclinical
development and clinical trials that are necessary for regulatory
approvals and to establish production, distribution, marketing and
sales, if such approvals are obtained.
Lack of necessary funds may require the Company to delay, reduce or
eliminate some or all of its research and product development programs
or to license its potential products or technologies to third parties.
The Company's diagnostic technology is at the pre-clinical, pre-revenue
stage and has not yet led to the development of any product.
There can be no assurance that any products that may be generated in
the future in the Company's programs will successful in the market.
Also, there can be no assurance that the Company will achieve revenues
from product sales or become profitable. Other risks and uncertainties
apply.
